Radiopharmaceutical · Kills target cells, directed at CD45 (PTPRC) · developed by Actinium Pharmaceuticals
131I-apamistamab is an iodine-131 radiolabeled anti-CD45 monoclonal antibody. It binds CD45, a protein on leukocytes, delivering targeted radiation, and is studied in acute myeloid leukemia, including relapsed or refractory disease and transplant-related settings.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07157514 | Phase 2/3 | Acute Leukemia | Not yet recruiting | ATNM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute LeukemiaAcute Myelogenous LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia, in RelapseAllogeneic DiseaseMyelogenous LeukemiaMyelogenous Leukemia in RelapseMyelogenous Leukemia, AcuteMyeloid LeukemiaRefractory AMLTransplant-Related Disorder
Updated Oct 11, 2026. Something wrong or missing? Report it on the ATNM page.
See ATNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ATNM catalysts and pipeline →